DK2344537T3 - Bispecifikke anti-vegf/anti-ang-2-antistoffer - Google Patents
Bispecifikke anti-vegf/anti-ang-2-antistofferInfo
- Publication number
- DK2344537T3 DK2344537T3 DK09736830.2T DK09736830T DK2344537T3 DK 2344537 T3 DK2344537 T3 DK 2344537T3 DK 09736830 T DK09736830 T DK 09736830T DK 2344537 T3 DK2344537 T3 DK 2344537T3
- Authority
- DK
- Denmark
- Prior art keywords
- ang
- vegf
- antibodies
- bispecific
- bispecific anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08017607 | 2008-10-08 | ||
EP08021834 | 2008-12-16 | ||
PCT/EP2009/007182 WO2010040508A1 (en) | 2008-10-08 | 2009-10-07 | Bispecific anti-vegf/anti-ang-2 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2344537T3 true DK2344537T3 (da) | 2014-02-10 |
Family
ID=41364494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09736830.2T DK2344537T3 (da) | 2008-10-08 | 2009-10-07 | Bispecifikke anti-vegf/anti-ang-2-antistoffer |
Country Status (32)
Country | Link |
---|---|
US (6) | US8268314B2 (da) |
EP (3) | EP2792687B1 (da) |
JP (2) | JP5368570B2 (da) |
KR (2) | KR20130118994A (da) |
CN (2) | CN102753577B (da) |
AR (1) | AR073775A1 (da) |
AU (1) | AU2009301431B8 (da) |
BR (1) | BRPI0919663A2 (da) |
CA (1) | CA2739122C (da) |
CL (1) | CL2011000769A1 (da) |
CO (1) | CO6351794A2 (da) |
CR (1) | CR20110166A (da) |
CY (1) | CY1115030T1 (da) |
DK (1) | DK2344537T3 (da) |
EC (1) | ECSP11010969A (da) |
ES (1) | ES2455217T3 (da) |
HK (2) | HK1172354A1 (da) |
HR (1) | HRP20140376T1 (da) |
IL (1) | IL211729A (da) |
MA (1) | MA32712B1 (da) |
MX (1) | MX2011003190A (da) |
MY (1) | MY178926A (da) |
NZ (1) | NZ591602A (da) |
PE (1) | PE20110425A1 (da) |
PL (1) | PL2344537T3 (da) |
PT (1) | PT2344537E (da) |
RU (2) | RU2542382C2 (da) |
SG (1) | SG195536A1 (da) |
SI (1) | SI2344537T1 (da) |
TW (2) | TWI458492B (da) |
WO (1) | WO2010040508A1 (da) |
ZA (1) | ZA201102203B (da) |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2390425T3 (es) | 2000-12-22 | 2012-11-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Uso de moléculas de orientación repulsivas (RGM) y sus moduladores |
US8906864B2 (en) | 2005-09-30 | 2014-12-09 | AbbVie Deutschland GmbH & Co. KG | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
EP2033971A1 (de) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
AU2008346734A1 (en) | 2008-01-03 | 2009-07-16 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8962803B2 (en) * | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
NO2344540T3 (da) | 2008-10-02 | 2018-04-28 | ||
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
CA2756244A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
WO2010136172A1 (en) * | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
RU2015153109A (ru) | 2009-09-16 | 2019-01-15 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применения |
UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
EP2488199A1 (en) * | 2009-10-14 | 2012-08-22 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
SG181563A1 (en) * | 2009-12-08 | 2012-07-30 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
SI2519543T1 (sl) * | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
PE20130643A1 (es) | 2010-07-12 | 2013-06-07 | Covx Technologies Ireland Ltd | Conjugados de anticuerpos multifuncionales |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
JP2013538338A (ja) | 2010-07-19 | 2013-10-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗癌治療への応答可能性の増大した患者を同定する方法 |
SG187018A1 (en) | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
KR20130100118A (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
CN102372778B (zh) * | 2010-08-19 | 2015-06-17 | 上海抗体药物国家工程研究中心有限公司 | 抗人vegf和opn双特异性抗体、其制备方法及用途 |
WO2012025530A1 (en) * | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
CN103403025B (zh) | 2011-02-28 | 2016-10-12 | 弗·哈夫曼-拉罗切有限公司 | 单价抗原结合蛋白 |
ES2549638T3 (es) | 2011-02-28 | 2015-10-30 | F. Hoffmann-La Roche Ag | Proteínas de unión a antígeno |
EP3318571B1 (en) | 2011-03-16 | 2021-02-17 | F. Hoffmann-La Roche AG | Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase |
AU2012227883A1 (en) | 2011-03-17 | 2013-10-24 | Ramot At Tel-Aviv University Ltd. | Bi- and monospecific, asymmetric antibodies and methods of generating the same |
US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
EP3431495A1 (en) * | 2011-10-20 | 2019-01-23 | ESBATech - a Novartis Company LLC | Stable multiple antigen-binding antibody |
BR112014013205A2 (pt) | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit |
CN102936277B (zh) * | 2011-12-29 | 2014-10-01 | 北京五康新兴科技有限公司 | 人血管内皮生长因子抗原表位及其表位疫苗 |
MY176695A (en) | 2012-01-27 | 2020-08-19 | Abbvie Inc | Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration |
KR20140127854A (ko) | 2012-02-10 | 2014-11-04 | 제넨테크, 인크. | 단일-쇄 항체 및 다른 이종다량체 |
JP6152120B2 (ja) | 2012-02-15 | 2017-06-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Fc受容体に基づくアフィニティークロマトグラフィー |
WO2013134414A1 (en) * | 2012-03-06 | 2013-09-12 | Galaxy Biotech, Llc | Bispecific antibodies with an fgf2 binding domain |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
EP2839019A4 (en) | 2012-04-20 | 2016-03-30 | Emergent Product Dev Seattle | CD3-BINDING POLYPEPTIDES |
TW201823460A (zh) * | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
WO2014001324A1 (en) | 2012-06-27 | 2014-01-03 | Hoffmann-La Roche Ag | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
RU2015100656A (ru) | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения |
KR20150038046A (ko) * | 2012-07-13 | 2015-04-08 | 에프. 호프만-라 로슈 아게 | 다중특이적 결합체의 탐지 방법 |
HUE056217T2 (hu) * | 2012-07-13 | 2022-02-28 | Roche Glycart Ag | Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében |
CN104768575B (zh) * | 2012-08-31 | 2017-09-08 | 国立大学法人大阪大学 | 含有vegf特异性表位和/或血管生成素‑2特异性表位的dna疫苗 |
JP2015532272A (ja) * | 2012-09-28 | 2015-11-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二重アンジオポエチン−2/Dll4結合剤および抗VEGF−R剤を含む薬学的組み合わせ |
AU2013322564A1 (en) * | 2012-09-28 | 2015-03-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual Angiopoietin-2 / Dll4 binders and anti-VEGF agents |
CA2887684A1 (en) | 2012-10-30 | 2014-05-08 | Peter Becker | Purification of polypeptides using dual stage tangential-flow ultrafiltration |
CA2890263C (en) | 2012-11-01 | 2020-03-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
EA201890895A1 (ru) | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | Мультивалентные и моновалентные мультиспецифические комплексы и их применение |
EP2992012B1 (en) * | 2013-04-29 | 2019-07-17 | F.Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
RU2687043C2 (ru) * | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
KR102131371B1 (ko) | 2013-07-02 | 2020-07-08 | 삼성전자주식회사 | Ang-2 특이적 항체 및 그의 용도 |
JP6283411B2 (ja) * | 2013-07-09 | 2018-02-21 | エービーエルバイオ | Dll4とvegfに特異的に結合する新規二重標的タンパク質とこれの用途 |
KR102060187B1 (ko) | 2013-07-19 | 2019-12-27 | 삼성전자주식회사 | Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도 |
EP3760639A1 (en) | 2013-09-08 | 2021-01-06 | Kodiak Sciences Inc. | Zwitterionic polymer conjugates |
MX2016003593A (es) | 2013-10-11 | 2016-06-02 | Hoffmann La Roche | Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico. |
CN103604923B (zh) * | 2013-10-22 | 2015-05-13 | 卫生部北京医院 | 检测抗甲状腺过氧化物酶和甲状腺球蛋白的天然双特异性抗体的试剂盒 |
KR102178323B1 (ko) | 2013-11-29 | 2020-11-13 | 삼성전자주식회사 | 항 c-Met/항 Ang2 이중 특이 항체 |
JP6568521B2 (ja) * | 2013-12-13 | 2019-08-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多価多重特異性分子の生物学的活性を決定するためのsprベースの架橋アッセイ |
MX2016008099A (es) * | 2013-12-20 | 2016-10-13 | Hoffmann La Roche | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40. |
EP3842455A1 (en) | 2014-01-15 | 2021-06-30 | F. Hoffmann-La Roche AG | Fc-region variants with improved protein a-binding |
AR100271A1 (es) | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Compuestos de vegfr2 / ang2 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
AU2015279560B2 (en) * | 2014-06-28 | 2020-09-17 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CN106573986A (zh) * | 2014-07-29 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
KR102390359B1 (ko) | 2014-09-29 | 2022-04-22 | 삼성전자주식회사 | 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체 |
KR20210013299A (ko) | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
CA2960797A1 (en) | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
AR102522A1 (es) * | 2014-11-06 | 2017-03-08 | Hoffmann La Roche | Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a |
BR112017009817A2 (pt) | 2014-11-10 | 2018-02-14 | Hoffmann La Roche | anticorpos anti-il-1beta e métodos de utilização |
SG11201703426PA (en) | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Anti-pdgf-b antibodies and methods of use |
BR112017009764A2 (pt) | 2014-11-10 | 2018-02-20 | Hoffmann La Roche | anticorpos biespecíficos e métodos de uso em oftalmologia |
KR20170082594A (ko) * | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | 항-ang2 항체 및 사용 방법 |
US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
AR103477A1 (es) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
CN104818295A (zh) * | 2015-02-03 | 2015-08-05 | 武汉友芝友生物制药有限公司 | 制备和筛选表达双特异性抗体细胞株的方法 |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
CN107849126B (zh) * | 2015-07-29 | 2022-04-08 | 阿勒根公司 | 仅有重链的抗ang-2抗体 |
MX2018002924A (es) * | 2015-09-14 | 2018-12-10 | Galaxy Biotech Llc | Anticuerpos monoclonales altamente potentes para factores angiogenicos. |
EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | CD3 BINDING POLYPEPTIDES |
CN108290958B (zh) * | 2015-10-02 | 2021-12-28 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
EP3150637A1 (en) * | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Multispecific antibodies |
SG10201911499TA (en) * | 2015-11-30 | 2020-01-30 | Pieris Australia Pty Ltd | Novel anti-angiogenic fusion polypeptides |
RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
US11008387B2 (en) | 2016-01-06 | 2021-05-18 | Order-Made Medical Research Inc. | Antibody inhibiting binding of VEGF to NRP1 |
CN108699141B (zh) | 2016-01-06 | 2022-06-17 | 定制药品研究株式会社 | 高亲和性抗vegf抗体 |
WO2017165681A1 (en) * | 2016-03-24 | 2017-09-28 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
WO2018007314A1 (en) * | 2016-07-04 | 2018-01-11 | F. Hoffmann-La Roche Ag | Novel antibody format |
US10836819B2 (en) | 2016-08-23 | 2020-11-17 | Medimmune Limited | Anti-VEGF-A and anti-ANG2 antibodies and uses thereof |
WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
WO2018122053A1 (en) | 2016-12-29 | 2018-07-05 | F. Hoffmann-La Roche Ag | Anti-angiopoietin-2 antibody formulation |
MX2019011141A (es) | 2017-03-22 | 2019-11-05 | Genentech Inc | Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares. |
CN108659112B (zh) * | 2017-03-30 | 2021-01-26 | 上海市同济医院 | 一种非对称双特异性抗体 |
BR112019017241A2 (pt) * | 2017-04-13 | 2020-04-14 | Agenus Inc | anticorpos anti-cd137 e métodos de uso dos mesmos |
CA3061053A1 (en) | 2017-06-02 | 2018-12-06 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
KR20200119274A (ko) | 2018-02-06 | 2020-10-19 | 에프. 호프만-라 로슈 아게 | 안과 질환의 치료 |
KR20200143436A (ko) * | 2018-04-13 | 2020-12-23 | 아피메트 게엠베하 | Nk 세포 결합 항체 융합 구조체 |
EP3805757A4 (en) * | 2018-06-04 | 2022-03-23 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR DETECTING A COMPLEX |
TW202016151A (zh) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
WO2020006511A1 (en) * | 2018-06-29 | 2020-01-02 | Gensun Biopharma, Inc. | Trispecific antagonists |
CA3105454A1 (en) | 2018-07-03 | 2020-01-09 | Catalent Pharma Solutions, Llc | Multifunctional protein molecules comprising decorin and use thereof |
MA53330A (fr) * | 2018-08-03 | 2021-06-09 | Amgen Inc | Constructions d'anticorps pour cldn18.2 et cd3 |
TW202021988A (zh) * | 2018-08-17 | 2020-06-16 | 三鈺生物科技股份有限公司 | 抗血管新生融合蛋白及其用途 |
US11066476B2 (en) | 2018-09-14 | 2021-07-20 | Shanghai tongji hospital | Asymmetric bispecific antibody |
US10894824B2 (en) * | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
EP3873519A1 (en) | 2018-10-29 | 2021-09-08 | F. Hoffmann-La Roche AG | Antibody formulation |
US20220185875A1 (en) * | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
JP2022537338A (ja) | 2019-06-19 | 2022-08-25 | エフ.ホフマン-ラ ロシュ アーゲー | 所定の構成の複数の発現カセットの標的指向性組込みによって二価二重特異性抗体発現細胞を作製するための方法 |
EP3986924A1 (en) | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
CA3145239A1 (en) * | 2019-08-06 | 2021-02-11 | Hugh LIN | Personalized treatment of ophthalmologic diseases |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
EP4061852A4 (en) * | 2019-11-21 | 2024-03-13 | Unity Biotechnology | ANTIBODIES TARGETED TO TIE-2 AND METHODS OF USE |
CN116234822A (zh) | 2020-07-07 | 2023-06-06 | 治纳辅医药科技有限公司 | 一种包括补体途径抑制剂和血管生成抑制剂的融合蛋白及其用途 |
WO2022011358A1 (en) * | 2020-07-10 | 2022-01-13 | Biomolecular Holdings Llc | Tetrahedral antibodies |
TW202221027A (zh) * | 2020-09-17 | 2022-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合vegf和ang-2的雙特異性抗原結合分子 |
US20220119536A1 (en) * | 2020-10-21 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Agonistic trkb binding molecules for the treatment of eye diseases |
US20220389120A1 (en) * | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
CN116265487A (zh) * | 2021-12-16 | 2023-06-20 | 三优生物医药(上海)有限公司 | 抗ang2-vegf双特异性抗体及其用途 |
CN116925234A (zh) * | 2022-04-02 | 2023-10-24 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
WO2023215783A1 (en) * | 2022-05-04 | 2023-11-09 | Kephera Diagnostics, Llc | Method for detecting lyme disease |
WO2024065268A1 (zh) * | 2022-09-28 | 2024-04-04 | 科兴生物制药股份有限公司 | 能够识别ang-2的抗体或抗原结合片段和同时识别vegf和ang-2的双抗 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
WO1991006305A1 (en) | 1989-11-07 | 1991-05-16 | Bristol-Myers Squibb Company | Oligomeric immunoglobulins |
WO1992004053A1 (en) | 1990-08-31 | 1992-03-19 | Bristol-Myers Sqibb Company | Homoconjugated immunoglobulins |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
CA2145985C (en) | 1992-10-28 | 2003-09-16 | Napoleone Ferrara | Vascular endothelial cell growth factor antagonists |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US5650490A (en) | 1994-10-07 | 1997-07-22 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 2 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5729577A (en) | 1996-05-21 | 1998-03-17 | Motorola, Inc. | Signal processor with improved efficiency |
US5917811A (en) | 1996-05-22 | 1999-06-29 | Qualcomm Incorporated | Method and apparatus for measurement directed hard handoff in a CDMA system |
EP0973804B1 (en) | 1997-04-07 | 2006-12-27 | Genentech, Inc. | Anti-vegf antibodies |
EP3260468A1 (en) | 1997-04-07 | 2017-12-27 | Genentech, Inc. | Anti-vegf antibodies |
EP1015480A2 (en) | 1997-08-18 | 2000-07-05 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
EP1049787B1 (en) | 1998-01-23 | 2004-11-24 | Vlaams Interuniversitair Instituut voor Biotechnologie | Multipurpose antibody derivatives |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
AU1687500A (en) | 1998-12-16 | 2000-07-03 | Kyowa Hakko Kogyo Co. Ltd. | Antihuman vegf monoclonal antibody |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
RU2430927C2 (ru) * | 2000-10-20 | 2011-10-10 | Тугаи Сейяку Кабусики Кайся | Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу |
US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
US6860472B2 (en) * | 2001-05-23 | 2005-03-01 | Suncor Stainless, Inc. | Quick rail system |
WO2003020906A2 (en) | 2001-08-31 | 2003-03-13 | Abmaxis, Inc. | Multivalent protein conjugate with multiple ligand-binding domains of receptors |
ES2276735T3 (es) | 2001-09-14 | 2007-07-01 | Affimed Therapeutics Ag | Anticuerpos fv multimericos de cadena sencilla en tandem. |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
JP5026072B2 (ja) | 2003-07-01 | 2012-09-12 | イミューノメディクス、インコーポレイテッド | 二重特異性抗体の多価キャリヤー |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US7485297B2 (en) * | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
CA2577133A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
EP1863844A1 (en) | 2005-02-28 | 2007-12-12 | Centocor, Inc. | Heterodimeric protein binding compositions |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
RU2515108C2 (ru) | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
WO2007068895A1 (en) | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
SG10201503407WA (en) | 2006-12-19 | 2015-06-29 | Genentech Inc | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
KR20100018040A (ko) | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
KR20100040840A (ko) | 2007-06-06 | 2010-04-21 | 도만티스 리미티드 | 폴리펩티드,항체 가변 도메인 및 길항제 |
KR20100052545A (ko) | 2007-08-28 | 2010-05-19 | 바이오겐 아이덱 엠에이 인코포레이티드 | Igf―1r의 다중 에피토프에 결합하는 조성물 |
RS53850B2 (sr) | 2007-10-30 | 2018-07-31 | Genentech Inc | Pročišćavanje antitela hromatografijom izmene katjona |
TW200944231A (en) | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
KR20110013409A (ko) | 2008-05-23 | 2011-02-09 | 삼성전자주식회사 | 항체-펩티드 융합 상승체 |
CN110372792A (zh) | 2008-06-25 | 2019-10-25 | 艾斯巴技术-诺华有限责任公司 | 抑制vegf的稳定和可溶的抗体 |
KR101705911B1 (ko) | 2008-09-03 | 2017-02-10 | 제넨테크, 인크. | 다중특이적 항체 |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
SI2376535T1 (sl) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t |
US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
MX346002B (es) | 2009-06-17 | 2017-03-01 | Abbvie Biotherapeutics Inc | Anticuerpos anti-vegf y sus usos. |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
UY32920A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
AU2011221229B2 (en) | 2010-02-23 | 2015-06-18 | F. Hoffmann-La Roche Ag | Anti-angiogenesis therapy for the treatment of ovarian cancer |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
EP3556776A1 (en) | 2012-05-31 | 2019-10-23 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists |
-
2009
- 2009-10-02 US US12/572,289 patent/US8268314B2/en active Active
- 2009-10-06 AR ARP090103839A patent/AR073775A1/es not_active Application Discontinuation
- 2009-10-07 PE PE2011000833A patent/PE20110425A1/es active IP Right Grant
- 2009-10-07 CN CN200980140164.1A patent/CN102753577B/zh active Active
- 2009-10-07 TW TW102101832A patent/TWI458492B/zh active
- 2009-10-07 DK DK09736830.2T patent/DK2344537T3/da active
- 2009-10-07 WO PCT/EP2009/007182 patent/WO2010040508A1/en active Application Filing
- 2009-10-07 BR BRPI0919663A patent/BRPI0919663A2/pt not_active Application Discontinuation
- 2009-10-07 NZ NZ591602A patent/NZ591602A/en unknown
- 2009-10-07 AU AU2009301431A patent/AU2009301431B8/en not_active Ceased
- 2009-10-07 ES ES09736830.2T patent/ES2455217T3/es active Active
- 2009-10-07 EP EP14152731.7A patent/EP2792687B1/en active Active
- 2009-10-07 KR KR1020137024840A patent/KR20130118994A/ko not_active Application Discontinuation
- 2009-10-07 KR KR1020117008184A patent/KR101345522B1/ko active IP Right Grant
- 2009-10-07 PL PL09736830T patent/PL2344537T3/pl unknown
- 2009-10-07 EP EP09736830.2A patent/EP2344537B1/en active Active
- 2009-10-07 TW TW098134012A patent/TWI393571B/zh not_active IP Right Cessation
- 2009-10-07 MY MYPI2011001540A patent/MY178926A/en unknown
- 2009-10-07 SI SI200930905T patent/SI2344537T1/sl unknown
- 2009-10-07 JP JP2011530411A patent/JP5368570B2/ja active Active
- 2009-10-07 CN CN201410195766.XA patent/CN103936860A/zh active Pending
- 2009-10-07 SG SG2013075361A patent/SG195536A1/en unknown
- 2009-10-07 RU RU2011117410/10A patent/RU2542382C2/ru not_active IP Right Cessation
- 2009-10-07 CA CA2739122A patent/CA2739122C/en not_active Expired - Fee Related
- 2009-10-07 MX MX2011003190A patent/MX2011003190A/es active IP Right Grant
- 2009-10-07 EP EP14152732.5A patent/EP2781526A1/en not_active Withdrawn
- 2009-10-07 PT PT97368302T patent/PT2344537E/pt unknown
-
2011
- 2011-03-14 IL IL211729A patent/IL211729A/en active IP Right Grant
- 2011-03-14 CO CO11031302A patent/CO6351794A2/es active IP Right Grant
- 2011-03-24 CR CR20110166A patent/CR20110166A/es unknown
- 2011-03-24 ZA ZA2011/02203A patent/ZA201102203B/en unknown
- 2011-04-06 CL CL2011000769A patent/CL2011000769A1/es unknown
- 2011-04-08 EC EC2011010969A patent/ECSP11010969A/es unknown
- 2011-04-13 MA MA33772A patent/MA32712B1/fr unknown
-
2012
- 2012-08-09 US US13/570,333 patent/US8703130B2/en active Active
- 2012-12-21 HK HK12113232.7A patent/HK1172354A1/xx unknown
-
2013
- 2013-09-09 JP JP2013186410A patent/JP2014039549A/ja active Pending
-
2014
- 2014-02-27 US US14/192,213 patent/US9708396B2/en active Active
- 2014-04-15 CY CY20141100279T patent/CY1115030T1/el unknown
- 2014-04-23 HR HRP20140376AT patent/HRP20140376T1/hr unknown
- 2014-12-09 RU RU2014149553A patent/RU2640253C2/ru active
- 2014-12-19 HK HK14112728.8A patent/HK1199265A1/xx unknown
-
2017
- 2017-05-23 US US15/603,124 patent/US20170369566A1/en not_active Abandoned
-
2020
- 2020-03-13 US US16/817,993 patent/US20210047394A1/en not_active Abandoned
-
2023
- 2023-01-05 US US18/150,616 patent/US20230399391A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2344537T3 (da) | Bispecifikke anti-vegf/anti-ang-2-antistoffer | |
CY2019004I2 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
BRPI0907532A2 (pt) | Anticorpos anti-c5ar humanizados | |
BRPI0819165A2 (pt) | Anticorpos anti-vegf | |
BRPI0923359A2 (pt) | Anticorpos anti-igf | |
BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
BRPI0906877A2 (pt) | Anticorpos anti-trkb aperfeiçoados | |
DK2131860T3 (da) | Anti-sclerostin-antistoffer | |
DK2459167T3 (da) | SUBKUTAN ANTI-HER2-antistofformulering | |
BRPI0912173A2 (pt) | anticorpos anti-flt3 | |
DK3072906T3 (da) | Antistofformulering | |
SMT201700083B (it) | Anticorpi monoclonali | |
CR20170001A (es) | Anticuerpos anti factor d humanizados | |
BRPI0922800A2 (pt) | anticorpos c-met | |
BRPI0821777A2 (pt) | Anticorpos biespecíficos bivalentes | |
DK2443154T3 (da) | Bispecifikke antigenbindingsproteiner | |
BRPI0919382A2 (pt) | anticorpos bi-específicos anti-egfr/anti-igf-1r | |
EP2259795A4 (en) | ANTI-VEGF ANTIBODY | |
BRPI0917148A2 (pt) | anticorpos anti-cd5 | |
EP2281845A4 (en) | STABLE POLYVALENT ANTIBODY | |
BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
BRPI0817427A2 (pt) | Anticorpo anti-bst2 | |
BRPI0912769A2 (pt) | anticorpos anti-pirb | |
TH0801006146A (th) | แอนติ-vegf แอนติบอดี | |
TH0901004529A (th) | แอนติบอดีสองจำเพาะต้าน vegf/ต้าน ang-2 |